Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CDK5RAP2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CDK5RAP2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CDK5RAP2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CDK5RAP2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CDK5RAP2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CDK5RAP2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CDK5RAP2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000734619 | Thyroid | PTC | regulation of mitotic cell cycle | 212/5968 | 457/18723 | 4.03e-11 | 1.44e-09 | 212 |
GO:003304419 | Thyroid | PTC | regulation of chromosome organization | 102/5968 | 187/18723 | 1.04e-10 | 3.58e-09 | 102 |
GO:0007163111 | Thyroid | PTC | establishment or maintenance of cell polarity | 115/5968 | 218/18723 | 1.15e-10 | 3.90e-09 | 115 |
GO:004477218 | Thyroid | PTC | mitotic cell cycle phase transition | 196/5968 | 424/18723 | 3.17e-10 | 1.02e-08 | 196 |
GO:0031334113 | Thyroid | PTC | positive regulation of protein-containing complex assembly | 121/5968 | 237/18723 | 5.70e-10 | 1.81e-08 | 121 |
GO:0010639112 | Thyroid | PTC | negative regulation of organelle organization | 163/5968 | 348/18723 | 3.04e-09 | 8.39e-08 | 163 |
GO:007050717 | Thyroid | PTC | regulation of microtubule cytoskeleton organization | 80/5968 | 148/18723 | 1.79e-08 | 4.19e-07 | 80 |
GO:003227327 | Thyroid | PTC | positive regulation of protein polymerization | 75/5968 | 138/18723 | 3.65e-08 | 8.02e-07 | 75 |
GO:01400148 | Thyroid | PTC | mitotic nuclear division | 135/5968 | 287/18723 | 4.90e-08 | 1.04e-06 | 135 |
GO:19019908 | Thyroid | PTC | regulation of mitotic cell cycle phase transition | 138/5968 | 299/18723 | 1.44e-07 | 2.78e-06 | 138 |
GO:19028509 | Thyroid | PTC | microtubule cytoskeleton organization involved in mitosis | 76/5968 | 147/18723 | 4.49e-07 | 7.38e-06 | 76 |
GO:003001020 | Thyroid | PTC | establishment of cell polarity | 74/5968 | 143/18723 | 6.05e-07 | 9.63e-06 | 74 |
GO:00457867 | Thyroid | PTC | negative regulation of cell cycle | 166/5968 | 385/18723 | 1.93e-06 | 2.64e-05 | 166 |
GO:19019878 | Thyroid | PTC | regulation of cell cycle phase transition | 167/5968 | 390/18723 | 2.97e-06 | 3.87e-05 | 167 |
GO:190211516 | Thyroid | PTC | regulation of organelle assembly | 88/5968 | 186/18723 | 7.41e-06 | 8.65e-05 | 88 |
GO:00459307 | Thyroid | PTC | negative regulation of mitotic cell cycle | 105/5968 | 235/18723 | 2.41e-05 | 2.39e-04 | 105 |
GO:00000705 | Thyroid | PTC | mitotic sister chromatid segregation | 79/5968 | 168/18723 | 2.78e-05 | 2.71e-04 | 79 |
GO:00070595 | Thyroid | PTC | chromosome segregation | 146/5968 | 346/18723 | 2.99e-05 | 2.87e-04 | 146 |
GO:00008196 | Thyroid | PTC | sister chromatid segregation | 92/5968 | 202/18723 | 3.07e-05 | 2.94e-04 | 92 |
GO:19019917 | Thyroid | PTC | negative regulation of mitotic cell cycle phase transition | 83/5968 | 179/18723 | 3.34e-05 | 3.17e-04 | 83 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CDK5RAP2 | SNV | Missense_Mutation | | c.1209N>C | p.Lys403Asn | p.K403N | Q96SN8 | protein_coding | deleterious(0.01) | possibly_damaging(0.601) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
CDK5RAP2 | SNV | Missense_Mutation | rs746903524 | c.2836C>T | p.Arg946Trp | p.R946W | Q96SN8 | protein_coding | deleterious(0.02) | benign(0.23) | TCGA-A2-A0YI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Femara | SD |
CDK5RAP2 | SNV | Missense_Mutation | rs151280101 | c.1488C>A | p.Phe496Leu | p.F496L | Q96SN8 | protein_coding | tolerated(1) | benign(0) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CDK5RAP2 | SNV | Missense_Mutation | novel | c.4591N>A | p.Gln1531Lys | p.Q1531K | Q96SN8 | protein_coding | tolerated(0.17) | benign(0.007) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
CDK5RAP2 | SNV | Missense_Mutation | | c.4539C>A | p.Ser1513Arg | p.S1513R | Q96SN8 | protein_coding | tolerated(0.19) | benign(0.003) | TCGA-A7-A4SD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
CDK5RAP2 | SNV | Missense_Mutation | novel | c.920N>A | p.Ala307Asp | p.A307D | Q96SN8 | protein_coding | deleterious(0.01) | possibly_damaging(0.532) | TCGA-A7-A6VV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
CDK5RAP2 | SNV | Missense_Mutation | | c.1201A>C | p.Ile401Leu | p.I401L | Q96SN8 | protein_coding | tolerated(0.19) | benign(0.006) | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CDK5RAP2 | SNV | Missense_Mutation | | c.1894T>G | p.Tyr632Asp | p.Y632D | Q96SN8 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-B6-A0I9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
CDK5RAP2 | SNV | Missense_Mutation | novel | c.314N>G | p.Glu105Gly | p.E105G | Q96SN8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A0BV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
CDK5RAP2 | SNV | Missense_Mutation | | c.5248N>A | p.Glu1750Lys | p.E1750K | Q96SN8 | protein_coding | tolerated(0.15) | benign(0.033) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |